Department of Internal Medicine, Yale University School of Medicine, New Haven, CT 06520, USA.
Department of Internal Medicine, Yale University School of Medicine, New Haven, CT 06520, USA.
Metabolism. 2019 Apr;93:1-9. doi: 10.1016/j.metabol.2018.12.003. Epub 2018 Dec 19.
Excessive adipose glucocorticoid action is associated with insulin resistance, but the mechanisms linking adipose glucocorticoid action to insulin resistance are still debated. We hypothesized that insulin resistance from excess glucocorticoid action may be attributed in part to increased ectopic lipid deposition in liver.
We tested this hypothesis in the adipose specific 11β-hydroxysteroid dehydrogenase-1 (HSD11B1) transgenic mouse, an established model of adipose glucocorticoid excess. Tissue specific insulin action was assessed by hyperinsulinemic-euglycemic clamps, hepatic lipid content was measured, hepatic insulin signaling was assessed by immunoblotting. The role of hepatic lipid content was further probed by administration of the functionally liver-targeted mitochondrial uncoupler, Controlled Release Mitochondrial Protonophore (CRMP).
High fat diet fed HSD11B1 transgenic mice developed more severe hepatic insulin resistance than littermate controls (endogenous suppression of hepatic glucose production was reduced by 3.8-fold, P < 0.05); this was reflected by decreased insulin-stimulated hepatic insulin receptor kinase tyrosine phosphorylation and AKT serine phosphorylation. Hepatic insulin resistance was associated with a 53% increase (P < 0.05) in hepatic triglyceride content, a 73% increase in diacylglycerol content (P < 0.01), and a 66% increase in PKCε translocation (P < 0.05). Hepatic insulin resistance was prevented with administration of CRMP by reversal of hepatic steatosis and prevention of hepatic diacylglycerol accumulation and PKCε activation.
These findings are consistent with excess adipose glucocorticoid activity being a predisposing factor for the development of lipid (diacylglycerol-PKCε)-induced hepatic insulin resistance.
过多的脂肪糖皮质激素作用与胰岛素抵抗有关,但将脂肪糖皮质激素作用与胰岛素抵抗联系起来的机制仍存在争议。我们假设,过多糖皮质激素作用引起的胰岛素抵抗部分归因于肝脏中异位脂质沉积的增加。
我们在脂肪组织特异性 11β-羟甾类脱氢酶-1(HSD11B1)转基因小鼠中检验了这一假设,该小鼠是脂肪糖皮质激素过多的成熟模型。通过高胰岛素-正葡萄糖钳夹试验评估组织特异性胰岛素作用,测量肝脂质含量,通过免疫印迹评估肝胰岛素信号。通过给予功能上靶向肝脏的线粒体解偶联剂——受控释放线粒体质子载体(CRMP)进一步探究肝脂质含量的作用。
高脂肪饮食喂养的 HSD11B1 转基因小鼠比同窝对照小鼠发展出更严重的肝胰岛素抵抗(内源性抑制肝葡萄糖生成减少了 3.8 倍,P<0.05);这反映在胰岛素刺激的肝胰岛素受体激酶酪氨酸磷酸化和 AKT 丝氨酸磷酸化减少。肝胰岛素抵抗与肝甘油三酯含量增加 53%(P<0.05)、二酰基甘油含量增加 73%(P<0.01)和 PKCε易位增加 66%(P<0.05)相关。CRMP 的给予可通过逆转肝脂肪变性和防止肝二酰基甘油积累和 PKCε激活来预防肝胰岛素抵抗。
这些发现与脂肪糖皮质激素活性过多是脂质(二酰基甘油-PKCε)诱导肝胰岛素抵抗发生的一个易感因素相一致。